‹ ›
MYP_118243
← PREVIOUS NEXT → BACK
Basic Information
P-70
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Standard
31 amino acids
C165H279N43O57
Standard
Sequence
INNYTSLIEELIKKSEEQQKKNEEELKKLEK
Physicochemical Analysis
3777.23 Da
5.30
-1.23
-1.45
-0.0395
-1.54
0.57
-0.39
73.60
88.06
0.0323
1490.00
1490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1713.23
-15.44
56.0
56.0
144.0
265.0
1.0
35.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0016971 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Defensin
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 JRCSF
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0059927 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells
0.0085±0.0005 μM
IC50
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0176065 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
HR2 fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 HXB2 | TZM-bl cells
0.0085±0.0005 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. | Chong H, Zhu Y, Yu D, He Y. | J Virol. 2018 Sep 26;92(20):e01088-18. | DOI:10.1128/JVI.01088-18 | PMID:30089693 PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0197268 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0288731 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
Bio-Activity Profile
Antimicrobial Antiviral
HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells
0.0497±0.0057 μM
IC50
PaperStructural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus. J Virol. 2018 Sep 26;92(20):e01088-18. doi: 10.1128/JVI.01088-18. PMID: 30089693. PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
1 2 NEXT LAST
Showing 5 records on this page · Page 1 of 2